Article info
PDFOesophagus
Original article
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer
- Correspondence to Dr Christopher J Lord, The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK; Chris.lord{at}icr.ac.uk
Citation
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer
Publication history
- Received April 27, 2017
- Revised July 16, 2017
- Accepted July 18, 2017
- First published August 22, 2017.
Online issue publication
September 07, 2018
Article Versions
- Previous version (22 August 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/